Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
暂无分享,去创建一个
A. Degramont | J. Meyerhardt | C. Bokemeyer | E. Van Cutsem | W. Harmsen | R. Goldberg | J. Tabernero | V. Heinemann | A. Grothey | L. Saltz | J. Zalcberg | H. Pitot | M. Koopman | M. Peeters | M. Rothenberg | N. Tebbutt | G. Masi | Q. Shi | T. Yoshino | D. Arnold | H. Schmoll | A. Sobrero | J. Souglakos | S. Lichtman | R. Adams | B. Giantonio | B. Chibaudel | J. Cleary | N. McCleary | P. M. Hoff | Ellana Haakenstad | M. Seymour
[1] Sudeep Gupta,et al. Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study , 2021, BMJ Open.
[2] Heiner Boeing,et al. The accumulation of deficits approach to describe frailty , 2019, PloS one.
[3] R. Labianca,et al. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. , 2018, European journal of cancer.
[4] Guifang Guo,et al. Proximal shift of colorectal cancer with increasing age in different ethnicities , 2018, Cancer management and research.
[5] H. Cohen,et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Kris,et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment , 2017, JAMA.
[7] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Julia H. Rowland,et al. Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[9] S. Moschos,et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. , 2016, Cancer treatment reviews.
[10] A. Shahrokni,et al. Long-term Toxicity of Cancer Treatment in Older Patients. , 2016, Clinics in geriatric medicine.
[11] Amy P Abernethy,et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.
[12] B. Reeve,et al. Impact of colorectal cancer diagnosis and treatment on health‐related quality of life among older Americans: A population‐based, case‐control study , 2015, Cancer.
[13] I. Browner,et al. Refining the chemotherapy approach for older patients with colon cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Mahmoud,et al. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC) , 2012, Journal of Cancer Research and Clinical Oncology.
[15] M. Hidalgo,et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. , 2012, The oncologist.
[16] J. Meyerhardt,et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Possinger,et al. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer , 2012, British Journal of Cancer.
[18] N. Petrelli,et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Parmar,et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial , 2011, The Lancet.
[20] H. Cohen,et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] V. Georgoulias,et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] J. Meyerhardt,et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Henry C. Pitot,et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Stephens,et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] C. Tournigand,et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer , 2007, Cancer.
[27] T. Hickish,et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years , 2007 .
[28] M. Extermann,et al. Comprehensive geriatric assessment for older patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] C. Tournigand,et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] H. Cohen,et al. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. , 2005, The oncologist.
[31] W. Scheithauer,et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] Harlan M Krumholz,et al. Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.
[33] S. Cantor,et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. , 2015, JAMA surgery.
[34] A. Shahrokni,et al. Cancer and Aging; Preparing for Silver Tsunami , 2015 .
[35] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[36] A. Carrato,et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). , 2011, Critical reviews in oncology/hematology.